Aras Azadian

Avicanna Inc. (OTCQX: AVCNF) a biopharmaceutical company specializing in proprietary cannabinoid-based products, announced Q3 2023 results late Tuesday, highlighted by the successful acquisition of Medical Cannabis by Shoppers assets, paving the way for the launch of the innovative MyMedi...

Regulation is among the factors inhibiting the flow of capital to cannabis innovation. Institutions are afraid to invest, and “big pharma is not coming in as we would like to see happen.” That is according to Aras Azadian, who joined the Benzinga Cannabis Capital Conference in Miami...

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Until recently, innovation lay dormant in the quality-driven cannabis industry. However, an evolving regulatory environment, coupled with...